FARON PHARMACEUTICALS OY

Report Publication Announcement • May 13, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1338Y

Faron Pharmaceuticals Oy

13 May 2016

Faron Pharmaceuticals Ltd

R&D Day - Save The Date

10.30-13.00

Tuesday, 14th June 2016

Panmure Gordon, One New Change, London, EC4M 9AF

Faron Pharmaceuticals Ltd ("Faron") is hosting an R&D Day which will take place on Tuesday, 14 June 2016. The event provides the opportunity to hear about the Company, its pipeline and R&D strategy. There will also be presentations from eminent Key Opinion Leaders - Prof Sirpa Jalkanen, a leading cell trafficking scientist in inflammation and cancer; Prof Geoff Bellingan, who is a world leading expert in Acute Respiratory Distress Syndrome (ARDS) and Principal Investigator of the INTEREST trial; and Prof David Adams, who directs the NIHR Birmingham Liver Biomedical Unit and is one of the leading scientists in liver diseases.

The event will take place at Panmure Gordon's offices, One New Change, London, EC4M 9AF.

If you are interested in attending the Faron Pharmaceuticals Ltd R&D Day or have any questions on the event, please contact Angelina De Souza Callaghan at angelina.desouzacallaghan@humebrophy.com or telephone +44 (0)20 7862 6397.

About Faron Pharmaceuticals Ltd.

Faron is a drug discovery and development company focused on creating novel treatments for medical conditions with significant unmet needs. The Company is based in Turku, Finland. The Company currently has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy and vascular damage. The Company's lead candidate Traumakine®, has been developed to treat Acute Respiratory Distress Syndrome ("ARDS"), a rare, severe, life-threatening medical condition characterised by widespread inflammation in the lungs. Traumakine® is now in a pan-European pivotal Phase III study (INTEREST). Besides Traumakine®, Faron's pipeline consists of early stage assets including a pre-clinical anti-Clever-1 antibody named Clevegen®. Clevegen® is focused on converting the immune environment around a tumour from being immune suppressive to immune stimulating and represents a novel immuno-oncology approach. Faron Pharmaceuticals is listed on AIM under the ticker 'FARN'. Further information is available at www.faronpharmaceuticals.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCATMFTMBTBBIF